BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Update: Napo Pharmaceuticals, Inc. Files Suit Against Salix Pharmaceuticals, Ltd. (SLXP) for Breach of Contract Pertaining to Lead Drug Candidate


5/6/2011 2:04:16 PM

By Suvarna Sheth, BioSpace.com

May 9, 2011 -- SAN FRANCISCO –- Napo Pharmaceuticals filed a lawsuit against Salix Pharmaceuticals in the state of New York on May 5, 2011, according to an undisclosed source. The lawsuit arises from Salix’s alleged fraudulent conduct and breaches of its contract relating to one of Napo’s primary pharmaceutical products, crofelemer.

Crofelemer is Napo’s propriety gastrointestinal compound still under development for four different indications: CRO-IBS for diarrhea-Predominant IBS (phase 2), CRO-HIV for AIDS-related diarrhea (phase 3), CRO-ID for acute infectious diarrhea (phase 2), and CRO-PED for pediatric diarrhea, (phase1).

Napo and Salix entered into an agreement for the license of crofelemer by Napo to Salix for all human indications of the drug in North America, Europe and Japan and for certain indications worldwide on December 9, 2008. According to the agreement, Salix was obligated to develop, manufacture and commercialize crofelemer for respective indications within areas licensed to it by Napo.

According to the court ordered summons, despite FDA “fast track status” NDA filing of the drug approaching in June 2011, Salix has failed to develop, manufacture and commercialize crofelemer for CRO-HIV for AIDS-related diarrhea.

Napo is claiming damages exceeding $150 million and seeks a declaratory judgment entitling Napo to terminate the collaboration agreement with Salix.

Based on a statement released from Salix Pharma today, Napo’s claims are "without merit and the lawsuit is baseless." The press release states that Salix intends to defend against the lawsuit and plans to continue with the development and commercialization of crofelemer in accordance with its past guidance and the terms of its Collaboration Agreement with Napo.

Napo Pharmaceuticals is based in San Francisco, Calif., and Salix Pharmaceuticals is based in North Carolina. Representatives for both companies have yet to return calls to BioSpace regarding this matter.

Read at BioSpace.com
Read at Business Wire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES